Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Biocartis   /   Biocartis forum geopend

Aandeel Biocartis BRU:BCART.BL, BE0974281132

Laatste koers (eur) Verschil Volume
0,290   0,000   (0,00%) Dagrange 0,000 - 0,000 0  

Biocartis forum geopend

Volgen
6.538 Posts
Pagina: «« 1 ... 271 272 273 274 275 ... 327 »» | Laatste | Omlaag ↓
  1. Sk&Dy 31 augustus 2022 18:33
    Tomorrow the H1 update is coming. Let's hope for a clear view on the interesting figures. There is no doubt that the course has already been severely penalized by the lack of view on the inflection point towards profitability as well as on doubts relating to funding details. Take advantage of this update to allay your questions. Interest in the stock can turn back when this inflection might be approaching or occurring.
  2. GoedeDag 31 augustus 2022 19:36
    quote:

    gigatron schreef op 31 augustus 2022 15:39:

    Oke ik bekijk het even anders en concentreer alles in één jaar. 1.000.000 cartridges voor 2000 idylla consoles. Dit komt neer op 500 cartridges per jaar per machine of 1,37 cartridges per dag per apparaat.Dit is naar mijn mening nog altijd bedroevend laag.
    Daar sta je dan met iets dat zeer snel resultaten kan genereren maar de hele dag stil staat.Als ze hun apparaten verkopen zonder winst kunnen ze hiermee de labo's overtuigen om eentje aan te schaffen. éénmaal ze het hebben wordt het enkel gebruikt in uitzonderlijke gevallen omdat de cartridges te duur zijn?.Misschien is er ook tegenkanting van het personeel die door idylla voor hun job vrezen? Weet eigenlijk iemand wat zo een idylla kost en wat zo een cartridge gemiddeld kost en hoeveel cartridges zo één machine maximaal per dag kan verbruiken?Ik weet niet wat het is maar er moet een grote fout zitten in hun initiëel businessplan.
    Voor alle duidelijkheid ik denk echt wel dat het kwalitatief een goed product is.Maar niet alle goede producten zijn commerciëel goede producten.
    Tja weet niet zo van hier maar in de US is het idee een vooraf ingevulde belastingsbrief die jij moet controleren en eventueel updaten afgevoerd omdat bedrijven die nu voor consumenten invullen dan zonder werk vallen. Pure omkoping ('lobbying'). Zolang ze in de US Idylla nog als RUO (Research Use Only) hebben registered zal dat niet exponentieel stijgen want dan betaalt de verzekering niets.

    Hier in de EU is dat anders maar denk niet dat Biocartis getallen van sold cartridges & Idylla's per continent geven.
  5. Stockbrood 1 september 2022 07:46
    Qua cijfers ziet het er goed uit. Vooral de stijging van de brutomarge staat mij aan. We hebben de laatste jaren altijd gewacht op exponentiële groei van de cartridgeverkoop maar het is vrij lineair gebleken. Dit wegens uitblijven van gamechangers.

    De impact door de herfinanciering vind ik moeilijk in te schatten: ik zie 25M uit een aandelenuitgifte met Voorkeursrecht.

    De rest is doorrollen van converteerbare obligaties en uittekenen van nieuwe converteerbare obligaties.
  13. forum rang 10 DeZwarteRidder 1 september 2022 09:30
    1
    PRESS RELEASE REGULATED INFORMATION/INSIDE INFORMATION
    1 September 2022, 07:00 CEST
    Biocartis Announces Entry into
    Comprehensive Recapitalization
    Arrangements to Strengthen Cash Position
    and Support Growth
    Mechelen, Belgium, 1 September 2022 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative
    molecular diagnostics company (Euronext Brussels: BCART), is pleased to announce a comprehensive recapitalisation
    transaction (the “Transactions”) that will provide adequate capital to support the Company’s growth for the
    foreseeable future. The Transactions are supported by key existing investors, and are a significant milestone for the
    Company. The Transactions will provide for the following:
    • Deleveraging via a partial equitization of the 4.00% convertible bonds due 2024 (“Existing Convertible
    Bonds”) equal to 10% of notional amounts outstanding, and maturity extension by 3.5 years to November
    2027.
    • Allow holders of the Existing Convertible Bonds to exchange into new second lien secured convertible bonds
    (“New Convertible Notes”), subject to their commitment to participate pro-rata in a fully backstopped EUR
    25 million investment into additional New Convertible Notes.
    • Allow existing shareholders to participate in the growth of the Company by taking part in a fully covered
    rights issue of EUR 25 million, which is backstopped in full by certain new investors and KBC Securities
    (subject to a number of customary and transaction specific conditions).
    • Certain existing holders of New Convertible Notes will provide a new senior secured term loan (“New
    Convertible Term Loans”) that will provide the Company with approximately EUR 16 million of additional
    cash liquidity.
    The Transactions are intended to provide the Company with approximately EUR 66 million of new money to help
    manage liquidity until the Company reaches operating breakeven.
    Herman Verrelst, Chief Executive Officer of Biocartis, said: “
    These financing arrangements represent a
    significant milestone for Biocartis. They provide us with an opportunity to strengthen our cash position by
    approximately EUR 66 million and fundamentally improve our financial structure by pushing out the maturity date on
    our convertible debt. Given the recent challenging conditions in the financing markets, we believe these arrangements
    represent an important validation of the Biocartis value proposition. Subject to the successful completion, and upon
    approval by our bondholders and shareholders, these agreements will provide the resources necessary to continue
    and execute our growth strategy towards profitability."
    The Transactions are subject to the consent of the requisite majority of the holders of the Existing Convertible Bonds
    and existing shareholders of the Company, and conditional upon equity proceeds in the fully backstopped rights
    offering of at least EUR 25 million. The Company has already received binding agreements from (i) certain holders of
    Existing Convertible Bonds to fully backstop approximately EUR 41 million of capital in the New Convertible Notes and
    New Convertible Term Loans, and (ii) certain new investors and KBC Securities to backstop (subject to a number of
    customary and transaction specific conditions) all of the EUR 25 million rights issue.
    The Company will call an extraordinary shareholders' meeting and a meeting of Existing Convertible Bond to request
    the necessary consents to effect the Transactions. The Company has already received commitment from 65% of
    holders of Existing Convertible Bonds. The Company believes that the Transactions are an important milestone for the
    Company to secure the financing necessary for its future growth which benefits all of its stakeholders and therefore
    encourages both shareholders and bondholders to grant the necessary consents to implement it. The Company intends
    to complete the Transactions by the end of the year.
  16. forum rang 10 DeZwarteRidder 1 september 2022 13:37
    1
    PRESS RELEASE REGULATED INFORMATION
    1 September 2022, 07:02 CEST
    BIOCARTIS ANNOUNCES H1 2022 RESULTS
    Affirms 2022 Outlook
    35% growth in oncology cartridge revenues
    Gross Margin on Products of 32%
    Refinancing underwayCompany will host a conference call with live webcast presentation today at 14:30 CEST / 13:30 BST (UK) / 08:30
    EDT (US) to discuss H1 2022 results
    Mechelen, Belgium, 1 September 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative
    molecular diagnostics company (Euronext Brussels: BCART), today announces its business highlights and financial
    results for the first half of 2022, prepared in accordance with IAS 34 ‘Interim Financial Reporting’ as adopted by
    the European Union.
    Commenting on the H1 2022 results and post-reporting period events, Herman Verrelst, Chief
    Executive Officer of Biocartis, said:
    “Our operational performance in H1 2022 marked a pivotal moment on our
    journey towards profitability: continued strong growth of our core oncology business translated into significantly
    higher gross margins. Cartridge revenue in our core oncology business grew by 35% year-on-year, and the gross
    margin on products increased to 32%. Despite the expected decrease of Idylla™ SARS-CoV-2 product sales, we
    almost quadrupled gross profit to EUR 6.6m during the first half of the year, fueled by increased average selling
    prices of cartridges in oncology and economies of scale in our cartridge manufacturing. We are on track to deliver
    on our objectives for the entire year, and also made important progress in securing future growth. We are
    particularly proud of the extended partnership with AstraZeneca for the development of a companion diagnostic
    for its blockbuster Tagrisso®. Furthermore, we were very pleased to announce that we entered into several
    financing arrangements with the support of certain holders of our convertible bonds. These will, upon successful
    completion, strengthen our cash position with approximately EUR 66m and fundamentally improve our financing
    structure.”
    KEY MESSAGES H1 2022
    ? Product revenue of EUR 20.3m (H1 2021: EUR 18.5m), of which EUR 16.5m from 153k cartridges sold and
    EUR 3.8m from instrument rentals and sales:
    ? EUR 14.4m cartridge revenue in oncology (+35% year-on-year), double-digit growth across all regions,
    led by the US, both in cartridge volumes as in Average Selling price (ASP)
    ? The contribution of COVID-19 testing to cartridge revenues decreased to EUR 1.7m as both volumes and
    pricing continued to reduce. Revenues are evenly split between Europe and the US
    ? ASP per commercial cartridge of EUR 113 in oncology and EUR 103 overall
    ? EUR 3.8m revenue from a global Idylla™ installed base of 2,014 instruments, with 102 net new instruments
    placed
    • Gross profit on product sales increased by 370% from EUR 1.4m to EUR 6.6m, reflecting a gross margin
    of 32%, compared to 8% for H1 2021 and 16% for the full year 2021
    • Operating cash burn1 of EUR -19.2m, EUR 9.4m lower than in H1 2021; Company cash position of EUR
    19.7m (unaudited figure) end of H1 2022. The available credit facilities of EUR 15.0m remained fully undrawn
    as of 30 June 2022
    • New partnership with AstraZeneca to develop a companion diagnostic2 (CDx) for use with Tagrisso®
    (osimertinib), AstraZeneca’s third-generation EGFR-TKI (tyrosine kinase inhibitor) treatment
    • Post the reporting period, start of Biocartis’ commercialization in Europe of SkylineDx’s Merlin Assay as
    a CE-IVD marked kit, ahead of the launch of an Idylla™ version of the Assay
    REFINANCING
    Today the Company announced a comprehensive recapitalization transaction (the ‘Transactions’) that will provide
    adequate capital to support the Company’s growth for the foreseeable future. The Transactions, which are
    supported by key existing investors, is a significant milestone for the Company and will provide for the following:
    • Deleveraging via a partial equitization of the 4.00% convertible bonds due 2024 (“Existing Convertible
    Bonds”) equal to 10% of notional amounts outstanding, and maturity extension by 3.5 years to
    1 EBITDA plus capital expenditure
    2 A companion diagnostic (CDx) test is a test used as a companion to a therapeutic drug that helps predict if a patient is likely to respond to a treatment or not
    2
    November 2027.
    • Allow holders of the Existing Convertible Bonds to exchange into new second lien secured convertible
    bonds (“New Convertible Notes”), subject to their commitment to participate pro-rata in a fully
    backstopped EUR 25 million investment into additional New Convertible Notes.
    • Allow existing shareholders to participate in the growth of the Company by taking part in a fully
    covered rights issue of EUR 25 million, which is backstopped in full by certain new investors and KBC
    Securities (subject to a number of customary and transaction specific conditions).
    • Certain existing holders of New Convertible Notes will provide a new senior secured term loan (“New
    Convertible Term Loans”) that will provide the Company with approximately EUR 16 million of
    additional cash liquidity.
    More information can be found in the press release here.
    2022 OUTLOOK
    As a result of a fading demand for COVID-19 testing, the product revenues for 2022 are projected to be around
    the lower end of the initial EUR 50-55m range, without any impact however on the previously stated expectations
    for gross margin on product sales and operating cash burn, which are maintained at:
    • Increase gross margins on product sales to 25% - 30%
    • Reduce the operating cash burn (EBITDA plus capital expenditure) by EUR 9.5m-13.5m, to be between
    EUR 43m - 47m for FY22
  18. forum rang 10 DeZwarteRidder 1 september 2022 17:32
    2022 OUTLOOK

    As a result of a fading demand for COVID-19 testing, the product revenues for 2022 are projected to be around the lower end of the initial EUR 50-55m range, without any impact however on the previously stated expectations for gross margin on product sales and operating cash burn, which are maintained at:

    • Increase gross margins on product sales to 25% - 30%

    • Reduce the operating cash burn (EBITDA plus capital expenditure) by EUR 9.5m-13.5m, to be between EUR 43m - 47m for FY22
  19. BEURSFANAAT 1 september 2022 21:39
    Sterke halfjaarcijfers :- brutowinst op product verkopen steeg met 370 procent tot 6,6 miljoen euro, wat een bruto marge van 32 procent betekent- duidelijkheid langverwachte herfinanciering- uitbreiding samenwerking met Astra Zeneca- verhogen inkomsten uit oncologiecartridges VS -aanhoudende groei Europa - groeiende bijdrage van Idylla genefusion, vandaag dan ook flink bijgekocht voor de toekomst, dat het vandaag een bloedrode algemene beurssentiment was ,juist goeie moment om bij te kopen maar dat moet ieder voor zichzelf uitmaken natuurlijk
  20. Aytroo 2 september 2022 11:02
    Optimisme van voorgaande reacties doen mij denken aan de laatste uren van de Titanic. Het orkest bleef ook 'in the mood' spelen om de passagiers een good feeling te geven en het schip niet te verlaten. Ondertussen scheurde de romp open en zoog de realiteit van het ijskoude water het schip naar de dieperik. Aandeel zakte gisteren naar zijn nieuw recordbodemkoers en verloor op één dag 20%.
6.538 Posts
Pagina: «« 1 ... 271 272 273 274 275 ... 327 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee